{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:56Z","timestamp":1787169596648,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,4,15]],"date-time":"2014-04-15T00:00:00Z","timestamp":1397520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s10067-014-2601-7","type":"journal-article","created":{"date-parts":[[2014,4,14]],"date-time":"2014-04-14T06:22:05Z","timestamp":1397456525000},"page":"981-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Anakinra treatment in patients with gout and type 2 diabetes"],"prefix":"10.1007","volume":"34","author":[{"given":"Antonio","family":"Vitale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,15]]},"reference":[{"key":"2601_CR1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1056\/NEJMcibr063500","volume":"355","author":"PH Joost","year":"2006","unstructured":"Joost PH, van Der Meer JW (2006) The inflammasome: a linebacker of innate defense. N Engl J Med 355:730\u2013732","journal-title":"N Engl J Med"},{"key":"2601_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"2601_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RHU.0b013e31827d8790","volume":"19","author":"BN Cronstein","year":"2013","unstructured":"Cronstein BN, Sunkureddi P (2013) Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol 19:19\u201329","journal-title":"J Clin Rheumatol"},{"key":"2601_CR4","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","volume":"52","author":"AE Butler","year":"2003","unstructured":"Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102\u2013110","journal-title":"Diabetes"},{"key":"2601_CR5","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793\u20131801","journal-title":"J Clin Invest"},{"key":"2601_CR6","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1073\/pnas.0305683101","volume":"101","author":"K Maedler","year":"2004","unstructured":"Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al (2004) Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 101:8138\u20138143","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2601_CR7","doi-asserted-by":"crossref","first-page":"17144","DOI":"10.1074\/jbc.M110.210526","volume":"286","author":"A Ardestani","year":"2011","unstructured":"Ardestani A, Sauter NS, Paroni F, Dharmadhikari G, Cho JH, Lupi R et al (2011) Neutralizing interleukin-1beta (IL-1beta) induces beta-cell survival by maintaining PDX1 protein nuclear localization. J Biol Chem 286:17144\u201317155","journal-title":"J Biol Chem"},{"key":"2601_CR8","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.2337\/db09-1199","volume":"59","author":"M Carstensen","year":"2010","unstructured":"Carstensen M, Herder C, Kivim\u00e4ki M, Jokela M, Roden M, Shipley MJ et al (2010) Accelerated increase in serum interleukin-1 receptor antagonist starts 6\u00a0years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 59:1222\u20131227","journal-title":"Diabetes"},{"key":"2601_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2796.2010.02313.x","volume":"269","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Blocking interleukin-1\u03b2 in acute and chronic autoinflammatory diseases. J Intern Med 269:16\u201328","journal-title":"J Intern Med"},{"key":"2601_CR10","doi-asserted-by":"crossref","unstructured":"Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol [Epub ahead of print]","DOI":"10.1016\/j.smim.2013.10.008"},{"key":"2601_CR11","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","volume":"9","author":"A So","year":"2007","unstructured":"So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9:R28","journal-title":"Arthritis Res Ther"},{"key":"2601_CR12","doi-asserted-by":"crossref","first-page":"R123","DOI":"10.1186\/ar4303","volume":"15","author":"S Ottaviani","year":"2013","unstructured":"Ottaviani S, Molt\u00f3 A, Ea HK, Neveu S, Gill G, Brunier L et al (2013) Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther 15:R123","journal-title":"Arthritis Res Ther"},{"key":"2601_CR13","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839\u20131848","journal-title":"Ann Rheum Dis"},{"key":"2601_CR14","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","volume":"64","author":"HR Schumacher Jr","year":"2012","unstructured":"Schumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64:1462\u20131470","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2601_CR15","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1126\/science.3086977","volume":"232","author":"K Bendtzen","year":"1986","unstructured":"Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232:1545\u20131547","journal-title":"Science"},{"key":"2601_CR16","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/oby.2010.55","volume":"18","author":"EJ Asseldonk van","year":"2010","unstructured":"van Asseldonk EJ, Stienstra R, Koenen TB, van Tits LJ, Joosten LA, Tack CJ et al (2010) The effect of the interleukin-1 cytokine family members IL-1\u00a0F6 and IL-1\u00a0F8 on adipocyte differentiation. Obesity (Silver Spring) 18:2234\u20132236","journal-title":"Obesity (Silver Spring)"},{"key":"2601_CR17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.berh.2012.07.009","volume":"26","author":"S Savic","year":"2012","unstructured":"Savic S, Dickie LJ, Wittmann M, McDermott MF (2012) Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Pract Res Clin Rheumatol 26:505\u2013533","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2601_CR18","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A, V\u00f8lund A, Ehses JA, Seifert B et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517\u20131526","journal-title":"N Engl J Med"},{"key":"2601_CR19","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","volume":"32","author":"CM Larsen","year":"2009","unstructured":"Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 32:1663\u20131668","journal-title":"Diabetes Care"},{"key":"2601_CR20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/13543784.2013.804060","volume":"22","author":"T Mandrup-Poulsen","year":"2013","unstructured":"Mandrup-Poulsen T, AIDA study group (2013) Interleukin-1 antagonists for diabetes. Expert Opin Investig Drugs 22:965\u2013979","journal-title":"Expert Opin Investig Drugs"},{"key":"2601_CR21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.25.022106.141627","volume":"27","author":"SL Masters","year":"2009","unstructured":"Masters SL, Simon A, Aksentijevich I, Kastner DL (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27:621\u2013668","journal-title":"Annu Rev Immunol"},{"key":"2601_CR22","doi-asserted-by":"crossref","unstructured":"Richette P, Clerson P, P\u00e9rissin L, Flipo RM, Bardin T (2013) Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2013-203779"},{"key":"2601_CR23","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/j.1756-185X.2011.01629.x","volume":"14","author":"AP Tran","year":"2011","unstructured":"Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14:e33\u2013e37","journal-title":"Int J Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2601-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-014-2601-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-014-2601-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T19:19:52Z","timestamp":1597691992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-014-2601-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["2601"],"URL":"https:\/\/doi.org\/10.1007\/s10067-014-2601-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,15]]}}}